Antiretroviral resistance and management after pre-exposure to prophylaxis

Lancet HIV. 2020 Feb;7(2):e84. doi: 10.1016/S2352-3018(19)30404-7.

Authors

Victoria Tittle¹, Marta Boffito², Alan McOwan³, Gary Whitlock³; Dean Street Collaborative Group

Affiliations

¹ HIV Department, Chelsea and Westminster Hospital, London SW10 9NH, UK. Electronic address: [email protected].
² HIV Department, Chelsea and Westminster Hospital, London SW10 9NH, UK; Department of Infectious Disease, Imperial College London, London, UK.
³ HIV Department, Chelsea and Westminster Hospital, London SW10 9NH, UK.

PMID: 32027853
DOI: 10.1016/S2352-3018(19)30404-7

No abstract available

Publication types

Comparative Study
Letter

MeSH terms

Adolescent
Adult
Aged
Anti-HIV Agents / therapeutic use*
Drug Resistance, Viral* / genetics
Female
Genotype
HIV Infections / drug therapy*
HIV Infections / prevention & control
HIV Infections / virology
Humans
Male
Middle Aged
Mutation
Pre-Exposure Prophylaxis*
Time-to-Treatment
Treatment Outcome
Viral Load / drug effects
Young Adult

Substances

Anti-HIV Agents